Skip to main content
Where are we with treating Pre-Rheumatoid Arthritis?

Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0530

Dr. John Cush RheumNow

3 years 9 months ago
Where are we with treating Pre-Rheumatoid Arthritis? Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0530, #1603 and #1604 shared at #ACR22. https://t.co/zWTFMgSmvA https://t.co/DYRUI4gfNU
While have come so far from the days of our patients living on massive doses of steroids, we still have many patients who use steroids for our diseases, with increasing data for toxicity, even in low dose. As someone much smarter than me described them, steroids are our best frenemy.
Hydroxychloroquine remains the backbone of treatment for SLE, and the only drug clinically proven to decrease mortality. Optimization of usage is therefore critical in maximizing benefit and preventing harms. Hydroxychloroquine blood level testing is available in clinical practice and can help guide this management. 
The assessment of disease activity in AxSpA involves the use of objective inflammatory response (OIR) and patient reported outcomes (PROs). In clinics, a combination of OIR and PROs are used to measure disease activity and response to treatment. OIR includes measurements such as CRP and MRI inflammatory lesions. PROs include measurements for pain, fatigue and quality of life (QOL).
Are we really treating Psoriatic disease if we only address active disease domains and T2T?

Dr. Rachel Tate ( @uptotate

Dr. John Cush RheumNow

3 years 9 months ago
Are we really treating Psoriatic disease if we only address active disease domains and T2T? Dr. Rachel Tate ( @uptotate) breaks down abstracts #0393 and #0387 and how the takeaways will apply to her practice. https://t.co/OrNZVUuvBZ https://t.co/UL4Hscjs4Z
Spondyloarthritis Topic Panel - #ACR22

SpA Panelists: Drs. Lianne Gensler, Antoni Chan, Akhil Sood, Eric Dein, Sheila

Dr. John Cush RheumNow

3 years 9 months ago
Spondyloarthritis Topic Panel - #ACR22 SpA Panelists: Drs. Lianne Gensler, Antoni Chan, Akhil Sood, Eric Dein, Sheila Reyes, Catherine Sims @synovialjoints @AkhilSoodMD @ericdeinmd @RHEUMarampa @DrCassySims https://t.co/No1AfHQf3k https://t.co/F9SHCOwwHC
Women vs. Men: Response to Treatment in Seronegative Arthritis

Dr. Janet Pope ( @Janetbirdope) discusses abstracts 16

Dr. John Cush RheumNow

3 years 9 months ago
Women vs. Men: Response to Treatment in Seronegative Arthritis Dr. Janet Pope ( @Janetbirdope) discusses abstracts 1614 and 1601 at #ACR22 https://t.co/9Safzla7OK https://t.co/cw6eoFBN58
Opioid and Neuropathic Use After Initiating btsDMARDs in RA

Dr. Julian Segan ( @JulianSegan) discusses Abstract 0925 a

Dr. John Cush RheumNow

3 years 9 months ago
Opioid and Neuropathic Use After Initiating btsDMARDs in RA Dr. Julian Segan ( @JulianSegan) discusses Abstract 0925 at #ACR22 https://t.co/H6g3zKQIlF https://t.co/sQp2pyiOTb
Treatment Considerations in Axial Spondyloarthritis

Dr. Lianne Gensler discusses treatment considerations in Axial SpA

Dr. John Cush RheumNow

3 years 9 months ago
Treatment Considerations in Axial Spondyloarthritis Dr. Lianne Gensler discusses treatment considerations in Axial SpA from #ACR22. -Abstract 0402 -Abstract 0388 -Abstract 0544 -Abstract 0545 https://t.co/kaPFMfchYG https://t.co/ll8HWutyLo
Can we alter neonatal gut microbiome to prevent spondyloarthritis?

Dr Chao ( @doctorRBC) discusses Abstract 0868 at th

Dr. John Cush RheumNow

3 years 9 months ago
Can we alter neonatal gut microbiome to prevent spondyloarthritis? Dr Chao ( @doctorRBC) discusses Abstract 0868 at the #ACR22. Abstract 0868: Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome https://t.co/1rlUWXbWjJ https://t.co/MRoOY0nGop
×